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Abstract  
Medicines Access Programs (MAP) offer access to publicly unfunded medicines at the 
discretion of pharmaceutical companies. Limited literature is available on their extent 
and scope in Australia and New Zealand. This study aims to identify MAPs for cancer 
medicines that were operational in 2014-15 in Australia and New Zealand  and 
describe their characteristics. A preliminary list of MAPs was sent to hospital 
pharmacists in Australia and New Zealand to validate and collect further information. 
Pharmaceutical companies were contacted directly to provide information regarding 
MAPs offered. Key stakeholders were interviewed to identify issues with MAPs. Fifty-
one MAPs were identified covering a range of indications. The majority of MAPs were 
provided free of charge to the patient for medicines that were registered or in the 
process of being registered but were not funded. Variability in the number of MAPs 
across institutions and characteristics was observed. Australia offered more MAPs 
than New Zealand. Only two of 17 pharmaceutical companies contacted agreed to 
provide information on their MAPs. Eight stakeholder interviews were conducted. This 
identified that while MAPs are widely operational there is lack of clinical monitoring, 
inequity to access, operational issues and lack of transparency. Our results suggest a 
need for a standardised and mandated policy to mitigate issues with MAPs.  
  
1. Introduction  
Granting access to new cancer medicines is a growing challenge for pharmaceutical 
insurance institutions because of the high cost of these medicines [1]. Both Australia 
and New Zealand  have implemented national medicines policies that aim for equitable 
and sustainable access to medicines [2]. Funding decisions are based on a rigorous 
value for money assessment that ensures subsidised access to medicines that have 
been estimated to be cost-effective. However, concerns have been raised on the 
delays in the regulatory approval and funding of new cancer medicines in these two 
countries compared to similar countries in Europe and the United States of America 
[3-5]. At the same time, the rise of targeted, individualised cancer medicine, promoted 
by mass media and social media campaigns has increased the demand for access to 
new cancer medicines.  
Outside clinical trials, compassionate use programs may be the only way for cancer 
patients to access expensive, new cancer medicines that are not yet approved by 
regulatory authorities or funded by a government. Internationally, there is no agreed 
terminology or nomenclature for compassionate use programs. In Australia, Medicine 
Access Programs (MAP) is an umbrella term for programs made available at the 
discretion of pharmaceutical companies that supply new and publicly unfunded 
medicines to patients either free of charge or at a reduced cost (Figure 1) [6]. These 
programs facilitate access in various situations such as the use of unapproved 
medicines, off-label use (use in a non-approved indication), lack of access to clinical 
trials (no active clinical trials are available or the patient does not meet the eligibility 
criteria), or ‘bridging’ time between the end of the clinical trial development, regulatory 
approval, funding recommendation and listing. They may also allow a  pharmaceutical 
company to supply an approved but publicly unfunded medicine to prescribers within 
certain parameters. In Australia, pharmaceutical companies can offer free medicines 
following registration in a Product Familiarisation Program which allows a health care 
professional to enroll a maximum of ten patients in the program [7]. 
MAPs may have both benefits and risks. The patient may benefit from an otherwise 
inaccessible medicine and the pharmaceutical company may get to promote its 
medicine, develop a future market share and lobby to obtain a successful 
recommendation for funding. However, critics argue that  MAPs are usually not 
sustainable, create equity issues for those unable to get access to the program or 
cannot afford the costs that may be incurred, and there is the potential for inadequate 
enrolment of patients [6]. New medicines do not have a well-established safety profile, 
may have uncertain clinical benefit and carry a risk of toxicity [8]. However, since MAPs 
in Australia and New Zealand are not required to be formally monitored, unlike clinical 
trials, there may be limited or no systematic recording of health outcomes and adverse 
drug events.  
Concerns have also been raised that some of these programs may be accessed by 
cancer patients who are desperate and vulnerable [9]. These programs may have a 
significant financial cost for the patients, provide questionable tangible benefits and 
place the patient at risk of severe toxicity. In 2015, Australian oncologists reported 
discussing unfunded cancer medicines with an average of 2.5 patients per month and  
prescribed them to an average of 0.9 patients per month [10]. Furthermore, it was 
observed that oncologists were prepared to recommend a cancer medicine that would 
cost their patients an average of AUD$ 9,395 per each additional month of survival 
[11].  
There is limited literature on the extent and scope of MAPs in Australia and New 
Zealand . A report funded by Medicines Australia (the peak body representing 
pharmaceutical companies in Australia) suggested that the MAPs for cancer 
medicines were widespread. It reported this from a sample of nine pharmaceutical 
companies in Australia that provided 28 cancer medicines via MAPs to more than 
4,700 patients in 2011 – 2012 [12]. However, it did not list the names of these 
medicines or the characteristics of those programs; nor did it gauge stakeholders’ 
perceptions and experiences of these programs. The objectives of the current 
exploratory study were to establish a list of MAPs and their characteristics (types of 
cancer/patient population covered, patient co-payment and the number of patients 
enrolled) in Australia and New Zealand  in the 2014-15 period. The stakeholders’ 
perceptions of MAPs were also investigated by surveying key stakeholders in the 
provision of MAPs in these countries.  
This study focused on formal MAPs organised by pharmaceutical companies which 
catered to more than one patient at a time. Information on one-off compassionate 
supply requests was not sought.  
2. Methods  
2.1 List of MAPs for cancer medicines  
A list of MAPs to cancer medicines and their respective characteristics in Australia and 
New Zealand was established through a survey of hospital pharmacists working in the 
area of oncology and a survey of pharmaceutical companies that market cancer 
medicines.  
2.1.1 Development of a preliminary list of MAPs  
A preliminary list of MAPs available in Australia and New Zealand  was developed 
using a literature review of published and unpublished reports, approaching key 
informants likely to have information on these programs and reviewing applications for 
new cancer medicines made to the Pharmaceutical Benefits Advisory Committee 
(PBAC) (which examines applications for funding in Australia) for subsidy between 
July 2013 and June 2015. The informants (oncologists, oncology pharmacists, 
members of drug and therapeutics advisory committees) were identified through the 
research team’s professional contacts. They were subsequently sent an email to 
explain the project and invited to provide information on MAPs. The objective of this 
step was to identify a preliminary list of cancer medicines that were offered through 
MAPs rather than focus on their characteristics.  
2.1.2 Survey of hospital pharmacists  
The preliminary list of MAPs was formulated into an online questionnaire using 
SurveyMonkey®. The preamble explained that the focal point of the survey was on 
formal programs offered to more than one patient at a time rather than a one-off supply 
to a particular patient. The questionnaire sought information on MAPs for cancer 
medicines available in Australia or New Zealand between January 2014 and July 
2015, programs still operational at the time the questionnaire was sent, the number of 
patients enrolled per program, types of cancer/patient population covered and the 
charge to the patient. Participants had the opportunity to add details of programs that 
were not on the list. The online survey was subsequently sent to members of The 
Society of Hospital Pharmacists of Australia (approximately 3,400 members) through 
the society’s newsletter and to the Cancer Pharmacist Group of The Clinical Oncology 
Society of Australia (157 members) and New Zealand’s Hospital Pharmacists’ 
Association (340 members) via email. The pharmacists were given two weeks to 
respond after which a reminder notification was sent. The survey instructions stated 
that a single response per institution was sufficient.  
The exact number of cancer centres in each country could not be established. Based 
on the national ‘Australian Hospital Statistics Report 2012-13’ there are likely to be 
fewer than 137 major hospitals in Australia [20]. New Zealand has 31 hospitals with 
pharmacy services [21]. 
2.1.3 Survey of pharmaceutical companies 
Pharmaceutical companies were approached directly to offer information on MAPs 
they provided. A list of pharmaceutical companies in Australia likely to be involved in 
marketing of cancer medicines was obtained through Medicines Australia’s website 
and funding applications to the PBAC. The company’s contact details were obtained 
from their Australasian website and a telephone call was made to identify the key 
team/personnel with which to liaise. Subsequently, an email was sent requesting 
information about the MAPs they provided in Australia and New Zealand. Companies 
were given two weeks to respond after which a reminder telephone call was made or 
an email sent to follow-up. All companies were given a time of four weeks to respond.  
2.1.4 Registration and funding status of medicines provided in MAPs. 
The registration and funding status of medicines provided in MAPs was ascertained in 
Australia and New Zealand by examining information posted on the medicine 
regulatory websites (Medsafe in New Zealand and the Therapeutic Goods 
Administration (TGA) in Australia) and the public funding agencies (PHARMAC in New 
Zealand and the Department of Health which administers the Pharmaceutical Benefits 
Scheme (PBS) in Australia including the Public Summary Documents pertaining to 
funding recommendations made by the Pharmaceutical Benefits Advisory Committee 
(PBAC)). MAPs were classified into three main categories: “no registration”, “no 
funding”, and “outside funding restrictions” for both countries. “No registration” applied 
to medicines that were not registered for the indication in the MAP until the end of the 
study period in July 2015. “No funding” applied to medicines that were registered but 
not funded for the indication during the study period. “Outside funding restrictions” 
applied to medicines that were both registered and funded for the indication and 
inferred to be used outside funding indications in MAPs (e.g. as a second-line 
treatment instead of first-line treatment or for patients who do not fulfil the clinical 
criteria outlined in the listing requirements).  
 
 2.2 Interview with key stakeholders  
Members from each key stakeholder group in Australia or New Zealand were invited 
to participate in a semi-structured interview. The stakeholder groups included 
oncologists, hospital pharmacists, cancer consumer organisations, cancer patients 
using MAPs, the Department of Health and Medicines Australia. The members were 
identified either through the research team’s professional contacts or through 
information available in the public domain. Interviews were either conducted face-to-
face or through Skype®. All interviews were recorded with permission. Questions 
focused on exploring interviewees’ understanding of MAPs, their benefits, risks, 
processes around implementation and future prospects.  
2.3 Data analysis  
Data on MAPs obtained from key informants in the preliminary stage, the hospital 
survey and the pharmaceutical companies’ survey was compiled to develop a list of 
MAPs. Characteristics of MAPs were summarised using descriptive analysis. 
Interviews were analysed using descriptive thematic analysis. Initially, the recordings 
were listened to by two members of the research team to identify the themes that 
emerged from the interviews. Following this, a group analysis session involving 
members of the research team was conducted to further refine the themes.  
2.4 Ethics approval  
Ethics approval for the study was granted by The University of Notre Dame’s Human 
Research Ethics Committee (reference 015060F).  
3. Results  
3.1 List and characteristics of MAPs  
Twenty-eight cancer centres in Australia and New Zealand responded to the survey. 
Nineteen responses were received from cancer centres in Australia and nine 
responses from centres in New Zealand. Fifty-one MAPs were identified as available 
in Australia and 36 in New Zealand in 2014-15. All programs available in New Zealand 
were also available in Australia. The programs covered a wide range of cancer types 
and patient population. A list of MAPs and their respective characteristics can be found 
in the Appendix.   
The median number of MAPs available per centre in Australia and New Zealand in 
2014-15 was 12.5 (range 1-34) overall, 17 in Australia (range 4-34) and 10 in New 
Zealand (range 1-14). The average number of patients per program in that period was 
22.  
Most (33, 65%) of the MAPs were provided free of charge to the patient while 12 (23%) 
had a cost-share arrangement between the patient and the pharmaceutical company 
with patient costs ranging from AUD $1,200 to $150,000. The payment arrangements 
for the remaining six (12%) MAPs could not be determined.  
Most MAPs in Australia were for medicines that were registered or in the process of 
being registered but were not funded (47.0%) or were likely to be used outside funding 
restrictions (39.2%) (Table 1). A higher proportion of MAPs in New Zealand compared 
to Australia was for medicines that were not registered (33%). The registered 
medicines in MAPs were not funded (41.6%) or were likely to be used outside funding 
restrictions (19.4%) (Table 1). 
3.2 Survey of pharmaceutical companies 
Australian branches of 17 pharmaceutical companies marketing cancer medicines 
were contacted. Over 50 telephone calls were made and more than 70 emails were 
sent to obtain responses. Two pharmaceutical companies, Gilead® and Bristol-Myers 
Squibb®, agreed to participate and provided the majority of the information requested. 
Bristol-Myers Squibb chose not to disclose the number of patients enrolled in its 
access programs. Thirteen companies declined to participate in the study citing 
commercial reasons for their decision. A response could not be obtained from the 
remaining two pharmaceutical companies despite numerous attempts at contact.  
3.3 Interviews with stakeholders  
Eight interviews were conducted to explore issues with MAPs. These included 
interviews with two oncologists, a group interview with five hospital pharmacists from 
the same hospital, another hospital pharmacist, a pharmaceutical policy adviser at the 
Department of Health, a MAP consumer, a senior manager at a national cancer charity 
and a representative from Medicines Australia. One pharmacist sent back written 
answers to the interview questions.  
Upon analysis of the stakeholders’ interviews, six major themes regarding MAPs were 
identified as described below.  
3.3.1 Benefits of MAPs 
Stakeholders acknowledged that MAPs fulfil an area of unmet access to medicines for 
certain patients. They facilitated access when the medicines were not routinely 
available for the patient or were needed as a “last-resort” treatment option. It was 
noticed that these medicines sometimes offered benefit to patients in terms of 
longevity and quality of life.  These programs were also reported to familiarise 
prescribers, through Product Familiarisation Programs, with medicines that were not 
yet routinely available.  
 “Patients who are expecting them and don’t have other options, don’t have to wait for 
as long. Side benefits include doctors become familiar with using them [medicines] 
and managing their patients on it.” (Representative from Medicines Australia)  
3.3.2 Ethical concerns  
As is evident from the quotes below, stakeholders were concerned about the ethical 
issues with access to MAPs. Stakeholders reported inequities of access as there 
was no organised forum for them to find out which programs were operational, 
eligibility criteria and processes to access them. The cost-share arrangement 
associated with some MAPs precluded certain patients with cancer from affording 
them. Whilst the majority of the MAPs were found to be provided free of charge to 
the patient, some attracted a high charge costing a patient up to AUD $150,000 per 
year (e.g. ruxolitinib (Jakavi®)). 
Some stakeholders also raised concerns about the potential discontinuation of supply 
of medicine to the patient post cessation of the program.  
“There are no contractual obligations to my knowledge for the company to keep 
supplying it [medicine].” (Oncologist)  
“Access would vary enormously based on clinician, company, therapeutic area and 
product development. I do not have enough visibility on similarities and differences 
between them.” (Representative from Medicines Australia)  
3.3.3 Administrative burden  
Pharmacists and prescribers reported increased administrative workload associated 
with MAPs without recognition of it or acknowledgement. The workload, at a pharmacy 
level, included setting up operating procedures for procurement, storage and 
dispensing of medicines. At a prescriber level it meant filling out applications to 
pharmaceutical companies for individual patients to procure the medicine, applying to 
the hospital’s drug and therapeutics committee for approval to prescribe the medicine, 
complying with the companies’ requirements for continued supply and writing 
prescriptions for repeat supply.  
"There is no awareness certainly at a prescriber and executive level that these 
programs are a different process at a pharmacy level than a regular medicine." 
(Pharmacist) 
3.3.4 Lack of clinical monitoring  
Stakeholders expressed concern that there were no mandated and standardised 
policies for patients to be clinically monitored whilst on these programs. These 
medicines have limited data on their safety and efficacy and a lack of adequate 
monitoring was reported to place patients at risk of toxicity and harm. Contrary to 
clinical trials there were also concerns that there were no formal requirements to 
collect any clinical data on patient outcomes.  
"Collection of data should be a condition of access." (Pharmaceutical policy adviser) 
“My understanding of most of the programs is that clinical data is collected but the 
level and variety will depend on therapeutic area, product [medicine] and clinician. The 
difficulty is mandating clinicians to collect data.” (Representative from Medicines 
Australia)  
3.3.5 Lack of transparency  
There was general consensus amongst stakeholders that there was a lack of 
transparency from pharmaceutical companies on aspects of MAPs. There was no 
clear information on which MAPs existed, types of cancer/patient population covered 
and ways to access them for individual patients. Some stakeholders also reported 
being bound by confidentiality agreements that did not allow them to discuss MAPs of 
which they had knowledge. The research team found, as noted above, that obtaining 
information from pharmaceutical companies on MAPs was challenging. However, the 
representative from Medicines Australia anticipated challenges that would be 
associated with greater marketing of MAPs.  
"Lack of transparency inevitably means there is inequity." (Pharmaceutical policy 
adviser) 
“The concern I have with complete transparency is the pressure it will put on clinicians 
and pharmaceutical companies to provide access to everyone even if it is not suitable 
for them.” (Representative from Medicines Australia)  
3.3.6 Future of MAPs 
Stakeholders urged that MAPs should be operated with greater patient monitoring and 
transparency from pharmaceutical companies. Most stakeholders were in favour of 
clinical data on patient outcomes being systematically collected and reported. Some 
suggested the establishment of a registry of MAPs allowing for uniformity in the 
awareness of operational MAPs, mitigating some issues around inequity of their 
access. Additionally, pharmacists suggested that remuneration for the administrative 
workload around MAPs was warranted.  
“They have to be run like trials. We run them like trials except we don’t charge.” 
(Pharmacist)  
These [MAPs] don’t go through the registry as far as I know. There is no data, I would 
prefer to see them run like clinical trials.” (Senior manager at a national cancer charity) 
“Current systems must be flexible enough in a transparent way to address community 
expectations with access in areas of high unmet clinical need.” (Pharmaceutical policy 
adviser) 
  
4. Discussion  
A total of fifty-one MAPs were available in Australia and New Zealand  in the 2014-
2015 period. This is substantially greater than the 28 MAPs identified in Medicines 
Australia’s report in 2011-2012 [12]. Several reasons may explain this higher number. 
The present study compiled information from different sources including from hospital 
pharmacists directly involved in the administration of these programs in cancer 
centres. Also, there is a possibility that the data reported by the respondents may have 
included information on cancer medicines provided to patients on an individual basis 
rather than in comprehensive programs organised by pharmaceutical companies.  
Most MAPs involved registered medicines or medicines close to registration but still 
publicly unfunded. MAPs are thus generally different from Expanded Access Programs 
in the United States of America  [13] or Compassionate Use programs in European 
states [14, 15] which involve investigational medicines exclusively. There are a 
number of reasons for this. In Australia, registration submissions are made later than 
to the U.S. Food and Drug Administration (FDA) or to the European Medicines Agency 
and registrations are even more delayed in New Zealand [3, 4]. Also, the time to 
positive funding decisions and actual listing appears to be longer in Australia and New 
Zealand than in some other countries [16]. For cancer medicines registered between 
2010 and 2016 in Australia, the average time between registration to the date of PBS 
listing was 18.6 months [17]. The existence of these MAPs is implicitly recognised by 
the PBAC as recommendations for funding may include grandfathering provisions. For 
example, vorinostat was recommended by the PBAC and included grandfathering 
provisions for patients who had accessed the medicine though the sponsor’s 
“Expanded Access Program” [18]. Furthermore, the PBAC may impose restrictions on 
the use of funded medicines considering that patients who do not fulfil the criteria may 
receive the medicine under a MAP. For example, the PBAC restricted the use of 
pembrolizumab to patients with metastatic melanoma who had not been previously 
exposed to ipilimumab while considering that the company will continue providing 
pembrolizumab to ipilimumab-refractory patients through a MAP [18]. In a number of 
cases, MAPs may start while the medicine has not been registered yet and access 
would need to be notified through the Special Access Scheme pathway. Once the 
medicine is registered but still unfunded, access may be provided under 
compassionate use or as a Product Familiarisation Program in Australia.  
MAPs can also be provided for medicines that are registered and funded but 
prescribing restrictions may limit use to specific indications or to patients who fulfil 
some conditions. For example, abiraterone was listed on the PBS in August 2013 but 
it had to be used in combination with the specified steroids only [19]. Enzalutamide 
was listed in December 2014 for metastatic prostate cancer but only as a second-line 
agent in patients who had received prior chemotherapy [20].  MAPs could then be 
provided at different stages during the regulatory life cycle of a medicine. For example, 
pembrolizumab could be provided before registration, between registration and PBS 
listing, and after listing to patients who do not fulfil the clinical restrictions of the PBS 
listing (i.e. who have not been previously exposed to ipilimumab).  
The average number of patients per MAP in this study was 22 which is much lower 
than the average of 169 patients per medicine found in Medicines Australia’s report 
[12]. This may be due to the fact that programs proposed in the period studied were 
used by a lower number of people on average though it is also likely that our results 
underestimated the number of patients actually on MAPs in Australia and New 
Zealand  because of the low response rate in our survey. According to documents 
released under the Freedom of Information Act 1982, the number of applications to 
the Australian Special Access Scheme for pembrolizumab was 170 between the 1st of 
January 2014 and 31 January 2015 [21]. Although it is not known how much of this 
usage was provided through MAPs, this number is higher than the estimate that can 
be drawn from the responses received in the present study (36). The PBAC application 
for vorinostat indicated “less than 10,000 active patients with CTCL [cutaneous T-cell 
lymphoma] receiving vorinostat treatment through the MSD [Merck Sharpe & Dohme] 
Expanded Access Program (EAP)” [18]. It is likely that MAPs actually cater to many 
more patients than what was observed in this study. However, the exact numbers are 
not made available publicly including in the Public Summary Documents released by 
the PBAC where these numbers are blacked out [18].  
Australia had more MAPs than New Zealand. The two countries differ significantly in 
their funding practices [2, 22]. New Zealand operates on a capped budget and spent 
less than half of Australia’s per capita medicine expenditure in 2011. Additionally, new 
cancer medicines in New Zealand were found to be less likely to be funded than in 
Australia [3, 23, 24]. Therefore, there may be less incentive for pharmaceutical 
companies to offer a medicine through MAPs as there is less chance of getting a 
positive funding decision. Patients may get subsidised access to unfunded medicines 
only in exceptional circumstances [25]. 
Interviews of stakeholders in this study confirmed previous reports in the literature that 
MAPs facilitated access to new cancer medicines for patients who had exhausted 
funded treatment options [8,26]. While enrolment in clinical trials of new medicines 
could still be a possibility, no active clinical trial may be available or patients may not 
fulfil the eligibility criteria. Access to international clinical trials of cancer medicines is 
limited as there may be only a few places kept for Australian patients [4]. New cancer 
medicines may also be unavailable because of long delays before regulatory approval, 
and between regulatory approval, funding and listing of medicines [4].  
The issue of lack of transparency on MAPs in Australia and New Zealand was a strong 
theme not only in the stakeholders’ interviews, but also in the survey of pharmaceutical 
companies. Only two of the 17 pharmaceutical companies surveyed agreed to provide 
information on MAPs they offered. It may be that pharmaceutical companies were 
unwilling to discuss some aspects of MAPs as it could be seen to promote access to 
these programs outside specific cancer centres and could lead to an unmanageable 
number of requests for access from patients. Open discussion of programs could also 
be perceived as direct promotion of prescription medicines to consumers which is 
currently prohibited in Australia. It could also interfere with the financial negotiations 
between these companies and the funding authorities. In developing the preliminary 
list of MAPs, some pharmacists (including some from leading cancer centres) and 
oncologists were unwilling to share information citing confidentiality agreements with 
pharmaceutical companies as the major reason. Cancer centres may also not be 
willing to advertise MAPs as they cannot manage to have patients coming from all 
over the country. However, consumers and health professionals would likely welcome 
the availability of publicly available information on MAPs.  
Stakeholders were concerned at the lack of clinical data collected and patient 
monitoring associated with MAPs. The lack of accountability, governance and scrutiny 
of these programs has the potential for harm to patients. Currently pharmaceutical 
companies are under no obligation to collect, monitor or report any clinical data on 
MAPs which differs from clinical trials which are governed by strict protocols [26]. 
Given medicines provided through MAPs can be investigational products or have only 
been used by a limited number of patients, their clinical benefit to patients could be 
uncertain and there may be a risk of toxicity. However, the collection of data within a 
MAP places legal obligations on pharmaceutical companies that would need to be 
further defined in Australian regulations. We note that data collection by prescribers 
and pharmacists would increase the already significant administrative burden these 
programs place them under. This was echoed in the discussion with pharmacists that 
manage these programs. It would be important to ensure that the administrative 
requirements of MAPs match the resource allocation for them.  
This study found large variations in the number of MAPs available at each centre. 
Some centres reported up to 34 MAPs had been available at some stage in 2014-15 
and some only one. These findings support the concerns raised by consumers, 
clinicians and pharmacists during the interviews about the lack of equity of access to 
MAPs across centres. Variability of access to MAPs is part of a wider issue with the 
variability of access to high cost medicines in Australian hospitals not listed on the 
PBS, as previously reported [27, 28]. These medicines have to be paid from hospital 
budgets, and the availability of resources and processes for allocating resources vary 
between hospitals and between states, resulting in some medicines being available in 
some hospitals but not in others.  
Another equity issue is the existence of cost-share arrangements as observed in 
approximately a quarter of these programs. High costs will preclude otherwise eligible 
patients from accessing medicines [30]. Unaffordable access to MAPs may represent 
a departure from current medicine policies that promote equitable access to medicines 
for all citizens [9].  
In May 2015, the Council of Australian Therapeutic Advisory Groups (CATAG) 
launched a set of guiding principles to facilitate appropriate governance and 
implementation of MAPs [6]. These intend to promote quality use of MAPs and prevent 
the likelihood of physical and financial harm to patients and hospitals. However, it is 
not known whether the principles captured by these guidelines are complied with in 
Australia, as these are neither mandated nor regulated. Current regulations for access 
to unapproved medicines in Australia (Special Access Scheme) and New Zealand   
(Section 29) only envisage individual access to unapproved medicines and are not 
suited to the regulation of programs which may enrol cohorts of patients like in MAPs 
[29, 30]. Such regulations have been implemented in the Expanded Access Programs 
in the US [13] and in some European countries for compassionate use of medicines 
[14, 15] with the objective to improve the protection of patients and the collection of 
safety data. In Australia, Product Familiarisation Programs following registration can 
be proposed [7]. However, no comprehensive information is publicly available on these 
programs. New provisions introduced in the 2015 edition of Medicines Australia’s 
Code of Conduct allow the collection of individual patient data under a formal protocol. 
This, however, is not mandated or monitored.  
In Australia, in response to two national reviews, the ‘Expert review of medicines and 
medical devices regulation’ and the Australian Senate’s inquiry on ‘Availability of new, 
innovative and specialist cancer drugs in Australia’ [4, 5, 31], a number of policy 
recommendations have been or are in the process of being implemented by the 
Australian Government. These include shorter registration processes with the priority 
review pathway [32], the provisional approval pathway [33] and the consideration of 
comparable overseas regulators’ assessment in the registration process [34]. In 
September 2017, Special Access Scheme processes have been improved [30]. In 
August 2017, a $13 million Rare Cancers and Rare Diseases research program to 
stimulate clinical trial activity may provide new avenues for patients with rare cancers 
to benefit from the latest research [35]. The implementation of managed access 
programs where funding is conditional to the provision of further scientific evidence 
may also decrease the need for MAPs in the future by bridging the gap between 
regulatory approval and the listing of medicines [2, 36].  
In New Zealand, a recent study funded by PHARMAC concluded that, in the absence 
of clinically significant health benefits provided by cancer medicines funded in 
Australia but not in New Zealand , “a policy of funding more new cancer medicines in 
order to achieve numerical parity with Australia or other countries would not result in 
substantive health improvement… and would not represent good value for money in 
terms of delivering the best health outcomes for all New Zealanders” [37]. 
The results of this study demonstrate a compelling need for greater transparency and 
accountability for MAPs. The findings create a strong case for collaboration between 
the stakeholders to promote safe, equitable and monitored use of MAPs. The 
existence of these programs is well recognised by all stakeholders including by the 
PBAC [38]. However, there is no legal or regulatory framework for MAPs. The use of 
unapproved medicines by significant number of patients outside clinical trials should 
be regulated as it is in other countries, for example the Expanded Access Programs 
for investigational drugs in the United States of America. Product Familiarisation 
Programs for approved medicines that are currently controlled under Medicines 
Australia’s code of conduct have no legal recognition. It is not clear whether the rules 
of Medicines Australia’s code of conduct also apply to medicines that are provided for 
compassionate use after registration. Ideally, the rules related to these programs 
should comply with the provisions outlined in the CATAG guidelines including: “any 
MAP should ensure uninterrupted supply, free of charge … for as long as the patient’s 
treating clinician determines that there is a clinical benefit and no equivalent or 
tolerated therapeutic alternative for the patient remains available Australia” [6]. There 
should be an open access registry for MAPs, which provides detailed information on 
the medicines and processes to follow, within a regulated framework as suggested by 
the CATAG guidelines.  
Limitations of the study  
This study has a number of limitations. The small number of respondents to the 
pharmacist survey may underestimate the actual number of patients on MAPs. The 
assessment of registration and funding status of medicines provided through MAPs 
was done on the basis of the limited information provided in the survey. It was not 
always possible to identify the exact indication(s) for which medicines were used and 
the indications may vary among patients and over time. Only a limited number of 
stakeholders were interviewed and the views expressed may not be representative of 
that stakeholder group as a selection bias may be present. The reliability of the 
comparison between the availability of MAPs in Australia and New Zealand  is limited 
by the small number of respondents in each country.  
5 Conclusion  
Medicines Access Programs are widely operational in Australia and New Zealand. 
These programs raise a number of important issues with regards to the lack of 
overarching regulatory policies, consistent governance, adequate information and 
protection of patients, outcome and safety monitoring, transparency and equity of 
access. A number of initiatives such as the publication of the CATAG guidelines may 
improve the current situation. Also, a collaborative approach is needed to drive 
standardised and mandated policies to mitigate issues with MAPs. Further research is 
required to enable a more comprehensive analysis of the MAPs in place overtime 
across Australia and New Zealand.   
Figure 1  
Access to new medicines in Australia and New Zealand  
 
Note: the Special Access Scheme in Australia and Section 29 in New Zealand regulate 
access to unapproved medicines. 
Table 1  Registration and funding status of medicines provided in MAPs in Australia 
and New Zealand 
 Australia New Zealand 
 Number Percentage  Number Percentage 
No 
registration 
6 11.8 12 33.3 
No funding 24 (10*) 47.0 15 (6*) 41.6 
Outside 
funding 
restrictions 
20 39.2 7 19.4 
Outside 
registered 
indications/no 
funding 
1 2.0 1 2.8 
Unknown 0 0 1 2.8 
 51 100 36 100 
*Registered during study period  
 
References 
[1] Ghinea N, Lipworth W. Affordable access to innovative cancer medicines - don't forget the 
prices. Med J Aust 2016; 204:214-5. 
[2] Babar ZUD, Vitry A. Differences in Australian and New Zealand medicines funding policies. 
Australian Prescriber 2014; 37:150-1. 
[3] Cheema PK, Gavura S, Migus M, Godman B, Yeung L, Trudeau ME. International variability in 
the reimbursement of cancer drugs by publically funded drug programs. Curr Oncol 2012; 19:E165-
E76. 
[4] The Senate Community Affairs References Committee. Availability of new, innovative and 
specialist cancer drugs in Australia. 2015; [Accessed 12 December 2015] 
http://www.aph.gov.au/Parliamentary_Business/Committees/Senate/Community_Affairs/Cancer_D
rugs.  
[5] Vitry A, Mintzes B, Lipworth W. Access to new cancer medicines in Australia: dispelling the 
myths and informing a public debate. Journal of Pharmaceutical Policy and Practice 2016; 9:13. 
[6] Council of Australian Therapeutic Advisory Groups. Managing Medicines Access Programs. 
Guiding principles for the governance of Medicines Access Programs in Australian hospitals. 2015; 
[Accessed 7 September 2016] http://www.catag.org.au/wp-content/uploads/2012/08/OKA10428-
CATAG-Guiding-Principles-for-Australian-Hospitals-FINAL-pdf.pdf  
[7] Medicines Australia. Code of Conduct Edition 18. 2015; [Accessed 7 September 2016] 
https://medicinesaustralia.com.au/code-of-conduct/code-of-conduct-current-edition/.  
[8] Lewis JRR, Lipworth W, Kerridge I, Doran E. Dilemmas in the compassionate supply of 
investigational cancer drugs. Intern Med J 2014; 44:841-5. 
[9] Azad A, Franco M. Co-funded expanded access programmes for new oncology drugs: 
creating a two-tier system for Australian cancer patients? Intern Med J 2013; 43:843-4. 
[10] Karikios DJ, Mileshkin L, Martin A, Ferraro D, Stockler M. Discussing and prescribing 
expensive unfunded anticancer drugs in Australia Asia-Pacific Journal of Clinical Oncology 2015; 
11:159-. 
[11] Karikios D. Oncologists'preferences for recommending expensive anticancer drugs. Asia-
Pacific Journal of Clinical Oncology 2016; 12:57. 
[12] Medicines Australia Oncology Industry Taskforce. Access to cancer medicines in Australia. 
2013; [Accessed 17 February 2015] http://medicinesaustralia.com.au/files/2013/07/Access-to-
oncology-medicines-1707-FINALV3.pdf.  
[13] Darrow JJ, Sarpatwari A, Avorn J, Kesselheim AS. Practical, Legal, and Ethical Issues in 
Expanded Access to Investigational Drugs. N Engl J Med 2015; 372:279-86. 
[14] Rahbari M, Rahbari NN. Compassionate use of medicinal products in Europe: current status 
and perspectives. Bull World Health Organ 2011; 89:163-. 
[15] Sou H. EU Compassionate use programmes (CUPs). Regulatory framework and points to 
consider before CUP implementation. Pharmaceutical medicine 2010; 24:223-9. 
[16] Wonder Drug Consulting. Analysis of submissions and outcomes for medicines for patients 
with cancer; an international comparison (2010-2016). 2017; [Accessed 13 November 2017] 
https://medicinesaustralia.com.au/wp-content/uploads/sites/52/2013/07/OIT_Project-
B_Report_Final_Oct16.pdf.  
[17] Consulting WD. Analysis of PBAC submissions and outcomes for medicines for patients with 
cancer (2010-2016). 2017; [Accessed 13 November 2017] https://medicinesaustralia.com.au/wp-
content/uploads/sites/52/2013/07/OIT_Project-A_Report_Final_Oct16.pdf.  
[18] Pharmaceutical Benefits Advisory Committee. Vorinostat: Capsule 100mg; Solinza® - Public 
Summary Document  March 2017. 2017; [Accessed 13 November 2017] 
http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2017-03/vorinostat-psd-
march-2017.  
[19] Pharmaceutical Benefits Advisory Committee. Abiraterone, tablet, 250 mg (as acetate), 
Zytiga® -  Public Summary Document November 2012. 2012; [Accessed 13 November 2017] 
http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2012-11/abiraterone.  
[20] Pharmaceutical Benefits Advisory Committee. Enzalutamide, capsule, 40 mg, Xtandi®, 
Astellas Pharma Australia Pty Ltd - Public Summary Document July 2014. 2014; [Accessed 13 
November 2017] http://www.pbs.gov.au/pbs/industry/listing/elements/pbac-meetings/psd/2014-
07/enzalutamide-psd-07-2014.  
[21] Therapeutics Goods Administration. Special Access Scheme - Category A Notifications from 1 
January 2014 to 31 January 2015. 2015; [Accessed 12 September 2016] 
https://www.tga.gov.au/sites/default/files/foi-169-1415-04.pdf.  
[22] Vogler S, Vitry A, Babar Z-U-D. Cancer drugs in 16 European countries, Australia, and New 
Zealand: a cross-country price comparison study. The Lancet Oncology 2015. 
[23] Wonder M, Milne R. Access to new medicines in New Zealand compared to Australia. The 
New Zealand medical journal 2011; 124:12-28. 
[24] Taylor C, Wonder M. Exploring the implications of a fixed budget for new medicines: a study 
of reimbursement of new medicines in Australia and New Zealand. Australian Health Review 2015; 
39:455-61. 
[25] PHARMAC. Exceptional circumstances. 2017; [Accessed 13 November 2017] 
https://www.pharmac.govt.nz/tools-resources/forms/exceptional-circumstances/.  
[26] Tie J, Gibbs P. Treatment with unfunded drugs in oncology: the impact of access 
programmes and clinical trials. Intern Med J 2013; 43:23-31. 
[27] Gallego G, Taylor SJ, Brien JAE. Provision of pharmaceuticals in Australian hospitals: equity of 
access? Pharm World Sci 2007; 29:47-50. 
[28] Gallego G, Taylor SJ, Brien JAE. Funding and access to high cost medicines in public hospitals 
in Australia: Decision-makers' perspectives. Health Policy 2009; 92:27-34. 
[29] Medsafe New Zealand. Use of unapproved medicines and unapproved use of medicines. 
2014; [Accessed 13 September 2016] http://www.medsafe.govt.nz/profs/riss/unapp.asp  
[30] Australian Government, Department of Health. Special Access Scheme. 2017; [Accessed 13 
November 2017] https://www.tga.gov.au/form/special-access-scheme.  
[31] Samson L, Delaat W, Horvath J. Review of medicines and medical devices regulation. Stage 
one report. 2015; [Accessed 12 December 2015] https://www.tga.gov.au/media-release/expert-
review-medicines-and-medical-devices-regulation.  
[32] Australian Government Department of Health. Priority review pathway: prescription 
medicines. 2017; [Accessed 13 November 2017] https://www.tga.gov.au/priority-review-pathway-
prescription-medicines.  
[33] Australian Government Department of Health. Consultation: Provisional Approval pathway 
for prescription medicines. 2017; [Accessed 13 November 2017] 
https://www.tga.gov.au/consultation/consultation-provisional-approval-pathway-prescription-
medicines.  
[34] Australian Government Department of Health. Consultation: Criteria for comparable 
overseas regulators. 2017; [Accessed 13 November 2017] 
https://www.tga.gov.au/consultation/consultation-criteria-comparable-overseas-regulators.  
[35] Australian Government, Department of Health. Rare Cancers and Rare Diseases - Research 
Grants. 2017; [Accessed 13 November 2017] 
https://www.health.gov.au/internet/main/publishing.nsf/Content/0C4D606ED8E85BC0CA25818500
1EAF82/%24File/MRFF_Rare_Cancers_Rare_Diseases_AUG_17.pdf.  
[36] Vitry A, Roughead E. Managed entry agreements for pharmaceuticals in Australia. Health 
Policy 2014; 117:345-52. 
[37] Evans J, Laking G, Strother M, Wang T, Metcalfe S, Blick G, Pauls R, Crausaz S. Mind the gap: 
An analysis of foregone health gains from unfunded cancer medicines in New Zealand. Semin Oncol 
2016; 43:625-37. 
[38] Pharmaceutical Benefits Advisory Committee. Pembrolizumab; 50 mg injection: powder for, 
1 vial, 100 mg injection: powder for, 1 vial; Keytruda® - Public Summary Document  March 2015 
2015; [Accessed 13 November 2017] http://www.pbs.gov.au/info/industry/listing/elements/pbac-
meetings/psd/2015-03/pembrolizumab-keytruda-psd-03-2015.  
 
